Selective CB2 receptor agonists. Part 2: Structure–activity relationship studies and optimization of proline-based compounds

[Display omitted] Through a ligand-based pharmacophore model (S)-proline based compounds were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1). Structure–activity relationship investigations for this compound class lead to oxo-pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2015-02, Vol.25 (3), p.581-586
Hauptverfasser: Riether, Doris, Zindell, Renee, Wu, Lifen, Betageri, Raj, Jenkins, James E., Khor, Someina, Berry, Angela K., Hickey, Eugene R., Ermann, Monika, Albrecht, Claudia, Ceci, Angelo, Gemkow, Mark J., Nagaraja, Nelamangala V., Romig, Helmut, Sauer, Achim, Thomson, David S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] Through a ligand-based pharmacophore model (S)-proline based compounds were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1). Structure–activity relationship investigations for this compound class lead to oxo-proline compounds 21 and 22 which combine an impressive CB1 selectivity profile with good pharmacokinetic properties. In a streptozotocin induced diabetic neuropathy model, 22 demonstrated a dose-dependent reversal of mechanical hyperalgesia.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2014.12.019